MA51155A - Compositions comprenant des polyribonucléotides circulaires et leurs utilisations - Google Patents
Compositions comprenant des polyribonucléotides circulaires et leurs utilisationsInfo
- Publication number
- MA51155A MA51155A MA051155A MA51155A MA51155A MA 51155 A MA51155 A MA 51155A MA 051155 A MA051155 A MA 051155A MA 51155 A MA51155 A MA 51155A MA 51155 A MA51155 A MA 51155A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions consisting
- circular polyribonucleotides
- polyribonucleotides
- circular
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762599547P | 2017-12-15 | 2017-12-15 | |
US201862676688P | 2018-05-25 | 2018-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51155A true MA51155A (fr) | 2020-10-21 |
Family
ID=66820668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051155A MA51155A (fr) | 2017-12-15 | 2018-12-14 | Compositions comprenant des polyribonucléotides circulaires et leurs utilisations |
Country Status (13)
Country | Link |
---|---|
US (8) | US20200306286A1 (fr) |
EP (1) | EP3724208A4 (fr) |
JP (2) | JP2021508490A (fr) |
KR (1) | KR20200127152A (fr) |
CN (1) | CN111819185A (fr) |
AU (2) | AU2018385757B2 (fr) |
BR (1) | BR112020011670A2 (fr) |
CA (1) | CA3084824A1 (fr) |
IL (1) | IL275205A (fr) |
MA (1) | MA51155A (fr) |
MX (1) | MX2020006150A (fr) |
SG (1) | SG11202005060YA (fr) |
WO (1) | WO2019118919A1 (fr) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020011670A2 (pt) | 2017-12-15 | 2020-11-17 | Flagship Pioneering Innovations Vi, Llc. | composições compreendendo polirribonucleotídeos circulares e seus usos |
CN112399860A (zh) | 2018-06-06 | 2021-02-23 | 麻省理工学院 | 用于在真核细胞中翻译的环状rna |
JP2022523794A (ja) | 2019-03-04 | 2022-04-26 | フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー | 環状ポリリボヌクレオチド及びその医薬組成物 |
CN111718929B (zh) * | 2019-03-20 | 2022-10-18 | 中国科学院上海营养与健康研究所 | 利用环形rna进行蛋白翻译及其应用 |
KR20210142678A (ko) | 2019-03-25 | 2021-11-25 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 변형된 원형 폴리리보뉴클레오티드를 포함하는 조성물 및 그의 용도 |
KR20220027855A (ko) | 2019-05-22 | 2022-03-08 | 매사추세츠 인스티튜트 오브 테크놀로지 | 원형 rna 조성물 및 방법 |
WO2020252436A1 (fr) | 2019-06-14 | 2020-12-17 | Flagship Pioneering Innovations Vi, Llc | Arn circulaires pour thérapie cellulaire |
EP3986469A1 (fr) | 2019-06-19 | 2022-04-27 | Flagship Pioneering Innovations VI, LLC | Compositions comprenant des polyribonucléotides circulaires pour la modulation de protéine et leurs utilisations |
US20220296729A1 (en) | 2019-06-19 | 2022-09-22 | Flagship Pioneering Innovations Vi, Llc | Methods of dosing circular polyribonucleotides |
CN112662659B (zh) * | 2019-10-15 | 2022-08-19 | 武汉核圣生物技术有限公司 | 一种普适性的mRNA体外环化方法 |
CA3160739A1 (fr) | 2019-12-04 | 2021-06-10 | Brian Goodman | Methodes et compositions d'arn circulaire |
EP4096681A1 (fr) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Administration de compositions comprenant des polyribonucléotides circulaires |
US20230181620A1 (en) | 2020-01-29 | 2023-06-15 | Flagship Pioneering Innovations Vi, Llc | Compositions for translation and methods of use thereof |
WO2021189059A2 (fr) * | 2020-03-20 | 2021-09-23 | Orna Therapeutics, Inc. | Méthodes et compositions d'arn circulaire |
JP2023527309A (ja) * | 2020-05-19 | 2023-06-28 | オルナ セラピューティクス インコーポレイテッド | 環状rna組成物及び方法 |
CA3179444A1 (fr) | 2020-05-20 | 2021-11-25 | Avak Kahvejian | Compositions immunogenes et leurs utilisations |
EP4153152A1 (fr) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de production d'anticorps polyclonaux humains |
CN116322760A (zh) | 2020-05-20 | 2023-06-23 | 旗舰创业创新第六有限责任公司 | 冠状病毒抗原组合物及其用途 |
CN111733243A (zh) * | 2020-06-29 | 2020-10-02 | 中山大学孙逸仙纪念医院 | 一种提高CircRNA检测准确率的方法 |
BR112022027110A2 (pt) * | 2020-07-01 | 2023-03-14 | Elevatebio Tech Inc | Composições e métodos para reprogramação celular usando rna circular |
EP4196139A2 (fr) | 2020-08-12 | 2023-06-21 | Actym Therapeutics, Inc. | Vaccins à base de bactéries immunostimulatrices, agents thérapeutiques et plateformes d'administration d'arn |
AU2021336976A1 (en) | 2020-09-03 | 2023-03-23 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
IL303892A (en) | 2020-12-23 | 2023-08-01 | Flagship Pioneering Innovations V Inc | In vitro assembly of RNA-encapsulating enalavirus capsids |
CN112562788B (zh) * | 2020-12-28 | 2022-06-28 | 上海交通大学 | 一种环状rna-rna结合蛋白关系预测模型构建方法 |
EP4116421A1 (fr) | 2021-03-10 | 2023-01-11 | Rznomics Inc. | Structure d'arn auto-circularisée |
TW202300650A (zh) | 2021-03-26 | 2023-01-01 | 美商旗艦先鋒創新有限責任(Vii)公司 | 真核系統中環狀多核糖核苷酸的產生 |
AR125216A1 (es) | 2021-03-26 | 2023-06-28 | Flagship Pioneering Innovations Vii Llc | Producción de polirribonucleótidos circulares en un sistema eucariota |
WO2022204466A1 (fr) | 2021-03-26 | 2022-09-29 | Flagship Pioneering Innovations Vii, Llc | Production de polyribonucléotides circulaires dans un système procaryote |
US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
KR20240035752A (ko) | 2021-05-18 | 2024-03-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 원형 폴리리보뉴클레오티드의 농축 방법 |
EP4341423A1 (fr) | 2021-05-18 | 2024-03-27 | Flagship Pioneering Innovations VI, LLC | Procédés d'enrichissement de polyribonucléotides circulaires |
US20230046606A1 (en) | 2021-07-15 | 2023-02-16 | Turn Biotechnologies, Inc. | Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use |
WO2023288287A2 (fr) | 2021-07-15 | 2023-01-19 | Turn Biotechnologies, Inc. | Constructions d'arn synthétiques, persistants et procédés d'utilisation pour le rajeunissement de cellules et pour le traitement |
WO2023009568A1 (fr) | 2021-07-27 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc | Dispositifs, systèmes et procédés de traitement |
WO2023044333A1 (fr) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Lipides cycliques et leurs procédés d'utilisation |
WO2023044343A1 (fr) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Lipides acycliques et leurs procédés d'utilisation |
EP4271818A1 (fr) | 2021-09-17 | 2023-11-08 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de production de polyribonucléotides circulaires |
TW202322826A (zh) | 2021-10-18 | 2023-06-16 | 美商旗艦先鋒創新有限責任公司 | 用於純化多核糖核苷酸之組成物及方法 |
WO2023073228A1 (fr) * | 2021-10-29 | 2023-05-04 | CureVac SE | Arn circulaire amélioré pour exprimer des protéines thérapeutiques |
WO2023086796A2 (fr) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Bactéries immunostimulatrices pour convertir des macrophages en un phénotype pouvant être traité, et diagnostic compagnon pour identifier des sujets pour un traitement |
WO2023096963A1 (fr) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Compositions d'immunogènes du virus varicelle-zona et leurs utilisations |
WO2023096990A1 (fr) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovation Vi, Llc | Compositions immunogènes de coronavirus et leurs utilisations |
WO2023097003A2 (fr) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Compositions immunogènes et leurs utilisations |
KR102488280B1 (ko) * | 2021-11-25 | 2023-01-16 | 주식회사 뉴클릭스바이오 | 신규한 부목 dna 및 이의 용도 |
WO2023115013A1 (fr) | 2021-12-17 | 2023-06-22 | Flagship Pioneering Innovations Vi, Llc | Procédés d'enrichissement en arn circulaire dans des conditions de dénaturation |
WO2023122745A1 (fr) | 2021-12-22 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Compositions et procédés de purification de polyribonucléotides |
WO2023122789A1 (fr) | 2021-12-23 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Polyribonucléotides circulaires codant pour des polypeptides antifusogènes |
WO2023122752A1 (fr) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Lipides contraints et procédés d'utilisation associés |
WO2023143541A1 (fr) * | 2022-01-28 | 2023-08-03 | Beijing Changping Laboratory | Vaccins à arn circulaire et leurs procédés d'utilisation |
WO2023196931A1 (fr) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Lipides cycliques et nanoparticules lipidiques (npl) pour l'apport d'acides nucléiques ou de peptides destinés à être utilisés dans la vaccination contre des agents infectieux |
US20240042021A1 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
WO2024054048A1 (fr) | 2022-09-06 | 2024-03-14 | 알지노믹스 주식회사 | Structure d'arn auto-circularisée |
WO2024054047A1 (fr) | 2022-09-06 | 2024-03-14 | 알지노믹스 주식회사 | Structure d'arn à auto-circularisation |
WO2024077191A1 (fr) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer |
KR102581491B1 (ko) * | 2023-01-20 | 2023-09-25 | 한국과학기술원 | mRNA의 세포내 안정성과 생합성을 향상시키는 래리엇 캡 구조의 RNA, 및 이의 용도 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
JPH06500014A (ja) | 1990-07-25 | 1994-01-06 | シンジーン,インコーポレイテッド | 多数の核酸相補体を生成させる環状伸長法 |
US5426180A (en) | 1991-03-27 | 1995-06-20 | Research Corporation Technologies, Inc. | Methods of making single-stranded circular oligonucleotides |
US5877160A (en) | 1991-05-31 | 1999-03-02 | Genta Incorporated | Compositions and methods of treatment of androgen-associated baldness using antisense oligomers |
US5639603A (en) | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
DK0604552T3 (da) | 1991-09-18 | 1997-08-04 | Affymax Tech Nv | Fremgangsmåde til syntese af forskellige samlinger af oligomerer |
AU683011B2 (en) | 1992-01-13 | 1997-10-30 | Duke University | Enzymatic RNA molecules |
US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
DE59309571D1 (de) | 1992-08-04 | 1999-06-17 | Thomson Brandt Gmbh | Hochspannungs-Zeilentransformator für einen Fernsehempfänger |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
US5565324A (en) | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
US5721099A (en) | 1992-10-01 | 1998-02-24 | Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
US5773244A (en) | 1993-05-19 | 1998-06-30 | Regents Of The University Of California | Methods of making circular RNA |
US5440016A (en) | 1993-06-18 | 1995-08-08 | Torrey Pines Institute For Molecular Studies | Peptides of the formula (KFmoc) ZZZ and their uses |
US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
US5688997A (en) | 1994-05-06 | 1997-11-18 | Pharmacopeia, Inc. | Process for preparing intermediates for a combinatorial dihydrobenzopyran library |
US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
US5688696A (en) | 1994-12-12 | 1997-11-18 | Selectide Corporation | Combinatorial libraries having a predetermined frequency of each species of test compound |
CA2225313A1 (fr) | 1995-06-21 | 1997-01-09 | Martek Biosciences Corporation | Banques combinatoires de composes biochimiques marques et procedes de production de telles banques |
US5766903A (en) * | 1995-08-23 | 1998-06-16 | University Technology Corporation | Circular RNA and uses thereof |
CA2158237A1 (fr) | 1995-09-13 | 1997-03-14 | Paolo Favaretto | Siege avec dossier pivotant |
US5731423A (en) | 1996-03-21 | 1998-03-24 | Transcell Technologies, Inc. | Process for preparing sulfoxides |
US6429301B1 (en) | 1998-04-17 | 2002-08-06 | Whitehead Institute For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
US6210931B1 (en) | 1998-11-30 | 2001-04-03 | The United States Of America As Represented By The Secretary Of Agriculture | Ribozyme-mediated synthesis of circular RNA |
AUPR604101A0 (en) | 2001-06-29 | 2001-07-26 | Unisearch Limited | Aptamers |
DE10132780A1 (de) * | 2001-07-06 | 2003-01-16 | Icon Genetics Ag | Plastidäre Genexpression über autonom replizierende Vektoren |
WO2003029459A2 (fr) | 2001-09-28 | 2003-04-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Molecules de micro-arn |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US20050069939A1 (en) * | 2003-09-26 | 2005-03-31 | Youxiang Wang | Amplification of polynucleotides by rolling circle amplification |
JP5243789B2 (ja) | 2004-03-15 | 2013-07-24 | シティ・オブ・ホープ | 二本鎖rnaによる遺伝子発現の特異的阻害のための方法及び組成物 |
US7601499B2 (en) * | 2005-06-06 | 2009-10-13 | 454 Life Sciences Corporation | Paired end sequencing |
CA2617561A1 (fr) | 2005-08-01 | 2007-02-08 | Purdue Research Foundation | Nano-particules d'arn multivalentes pour distribution de principes actifs a une cellule |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
JP5296328B2 (ja) | 2007-05-09 | 2013-09-25 | 独立行政法人理化学研究所 | 1本鎖環状rnaおよびその製造方法 |
US8513207B2 (en) | 2008-12-18 | 2013-08-20 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
WO2010084371A1 (fr) | 2009-01-26 | 2010-07-29 | Mitoprod | Nouvelles molécules d'arn interférent circulaire |
KR101938548B1 (ko) | 2011-06-23 | 2019-01-15 | (주)아모레퍼시픽 | 마이크로 rna를 포함하는 색소형성유전자 발현조절용 조성물 |
WO2013053481A1 (fr) | 2011-10-11 | 2013-04-18 | Secutech International Pte. Ltd. | Diméthylsulfoxyde utilisé comme solvant pour des acides nucléiques |
WO2013113326A1 (fr) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide |
WO2013118878A1 (fr) * | 2012-02-09 | 2013-08-15 | 独立行政法人理化学研究所 | Arn cyclique et procédé d'obtention de protéine |
AU2013243949A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
EP2833920A2 (fr) | 2012-04-02 | 2015-02-11 | Moderna Therapeutics, Inc. | Polynucléotides modifiés destinés à la production de produits biologiques et de protéines associées à une maladie humaine |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
RS64622B1 (sr) | 2012-05-25 | 2023-10-31 | Univ California | Metode i sastavi za modifikaciju ciljane dnk upravljenu pomoću rnk i za modulaciju transkripcije upravljanu rnk |
US20150299702A1 (en) | 2012-11-30 | 2015-10-22 | Aarhus Universitet | Circular rna for inhibition of microrna |
US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
DE102013005361A1 (de) | 2013-03-28 | 2014-10-02 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Polyribonucleotid |
WO2014186334A1 (fr) | 2013-05-15 | 2014-11-20 | Robert Kruse | Traduction intracellulaire d'arn circulaire |
KR20160036065A (ko) | 2013-08-16 | 2016-04-01 | 라나 테라퓨틱스, 인크. | Rna를 조정하기 위한 조성물 및 방법 |
US20160194368A1 (en) * | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
EP3058082A4 (fr) * | 2013-10-18 | 2017-04-26 | ModernaTX, Inc. | Compositions et procédés pour tolériser des systèmes cellulaires |
SG11201608798YA (en) | 2014-04-23 | 2016-11-29 | Modernatx Inc | Nucleic acid vaccines |
AU2015289656A1 (en) * | 2014-07-16 | 2017-02-16 | Modernatx, Inc. | Circular polynucleotides |
EP3054017A1 (fr) | 2015-02-03 | 2016-08-10 | Johann Wolfgang Goethe-Universität, Frankfurt am Main | ARN circulaire pour le diagnostic et traitement de maladies cardiovasculaires |
US10227594B2 (en) | 2015-03-20 | 2019-03-12 | Conopco, Inc. | Antiperspirant composition |
EP4219532A3 (fr) | 2015-06-05 | 2023-08-16 | Dana-Farber Cancer Institute, Inc. | Compositions et procédés pour une thérapie génique transitoire à stabilité améliorée |
DE112016002962T5 (de) * | 2015-06-30 | 2018-05-24 | Ethris Gmbh | Familie der ATP-bindenden Kassetten-codierende Polyribonucleotide und Formulierungen derselben |
KR20180048743A (ko) * | 2015-09-04 | 2018-05-10 | 토카겐 인크. | 2a 펩타이드를 포함하는 재조합 벡터 |
US11814627B2 (en) | 2016-06-20 | 2023-11-14 | The Board Of The Leland Stanford Junior University | Circular RNAs and their use in immunomodulation |
CN106222174B (zh) * | 2016-08-12 | 2020-08-04 | 青岛大学 | circRNA CHIF核苷酸在治疗心脏疾病中的用途 |
US11753434B2 (en) | 2017-04-14 | 2023-09-12 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for transient gene therapy with enhanced stability |
WO2018237372A1 (fr) | 2017-06-23 | 2018-12-27 | Cornell University | Molécules d'arn, procédés de production d'arn circulaire, et procédés de traitement |
BR112020011670A2 (pt) | 2017-12-15 | 2020-11-17 | Flagship Pioneering Innovations Vi, Llc. | composições compreendendo polirribonucleotídeos circulares e seus usos |
CN112399860A (zh) | 2018-06-06 | 2021-02-23 | 麻省理工学院 | 用于在真核细胞中翻译的环状rna |
AU2019312269A1 (en) | 2018-07-24 | 2021-03-04 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
CN111603477B (zh) | 2019-02-25 | 2023-06-02 | 中国科学院分子细胞科学卓越创新中心 | 环形rna在系统性红斑狼疮制备治疗药物中的应用 |
US20220142896A1 (en) | 2019-03-01 | 2022-05-12 | Flagship Pioneering Innovations Vi, Llc | Polyribonucleotides and cosmetic uses thereof |
MA55082A (fr) | 2019-03-01 | 2022-01-05 | Flagship Pioneering Innovations Vi Llc | Compositions, procédés, et kits pour l'administration de polyribonucléotides |
JP2022523794A (ja) | 2019-03-04 | 2022-04-26 | フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー | 環状ポリリボヌクレオチド及びその医薬組成物 |
KR20210142678A (ko) | 2019-03-25 | 2021-11-25 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 변형된 원형 폴리리보뉴클레오티드를 포함하는 조성물 및 그의 용도 |
WO2020252436A1 (fr) | 2019-06-14 | 2020-12-17 | Flagship Pioneering Innovations Vi, Llc | Arn circulaires pour thérapie cellulaire |
US20220296729A1 (en) | 2019-06-19 | 2022-09-22 | Flagship Pioneering Innovations Vi, Llc | Methods of dosing circular polyribonucleotides |
EP3986469A1 (fr) | 2019-06-19 | 2022-04-27 | Flagship Pioneering Innovations VI, LLC | Compositions comprenant des polyribonucléotides circulaires pour la modulation de protéine et leurs utilisations |
US20230181620A1 (en) | 2020-01-29 | 2023-06-15 | Flagship Pioneering Innovations Vi, Llc | Compositions for translation and methods of use thereof |
EP4096681A1 (fr) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Administration de compositions comprenant des polyribonucléotides circulaires |
EP4096715A1 (fr) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Compositions comprenant des polyribonucléotides linéaires pour la modulation de protéine et leurs utilisations |
EP4153152A1 (fr) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de production d'anticorps polyclonaux humains |
CA3179444A1 (fr) | 2020-05-20 | 2021-11-25 | Avak Kahvejian | Compositions immunogenes et leurs utilisations |
CN116322760A (zh) | 2020-05-20 | 2023-06-23 | 旗舰创业创新第六有限责任公司 | 冠状病毒抗原组合物及其用途 |
-
2018
- 2018-12-14 BR BR112020011670-0A patent/BR112020011670A2/pt unknown
- 2018-12-14 US US16/772,678 patent/US20200306286A1/en active Pending
- 2018-12-14 AU AU2018385757A patent/AU2018385757B2/en active Active
- 2018-12-14 EP EP18887999.3A patent/EP3724208A4/fr active Pending
- 2018-12-14 JP JP2020552672A patent/JP2021508490A/ja active Pending
- 2018-12-14 KR KR1020207019809A patent/KR20200127152A/ko unknown
- 2018-12-14 SG SG11202005060YA patent/SG11202005060YA/en unknown
- 2018-12-14 CA CA3084824A patent/CA3084824A1/fr active Pending
- 2018-12-14 MA MA051155A patent/MA51155A/fr unknown
- 2018-12-14 CN CN201880081133.2A patent/CN111819185A/zh active Pending
- 2018-12-14 WO PCT/US2018/065836 patent/WO2019118919A1/fr unknown
- 2018-12-14 MX MX2020006150A patent/MX2020006150A/es unknown
-
2019
- 2019-06-11 US US16/438,073 patent/US10953033B2/en active Active
-
2020
- 2020-06-08 IL IL275205A patent/IL275205A/en unknown
-
2021
- 2021-02-11 US US17/173,991 patent/US11058706B2/en active Active
- 2021-05-06 US US17/313,963 patent/US11160822B2/en active Active
- 2021-09-22 US US17/482,346 patent/US11458156B2/en active Active
-
2022
- 2022-08-30 US US17/898,947 patent/US20230070937A1/en active Pending
- 2022-11-16 US US17/988,007 patent/US11844759B2/en active Active
-
2023
- 2023-07-04 JP JP2023109861A patent/JP2023126888A/ja active Pending
- 2023-12-18 US US18/543,966 patent/US20240122959A1/en active Pending
-
2024
- 2024-01-17 AU AU2024200298A patent/AU2024200298A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200306286A1 (en) | 2020-10-01 |
JP2023126888A (ja) | 2023-09-12 |
SG11202005060YA (en) | 2020-06-29 |
EP3724208A1 (fr) | 2020-10-21 |
US11844759B2 (en) | 2023-12-19 |
US20240122959A1 (en) | 2024-04-18 |
US10953033B2 (en) | 2021-03-23 |
EP3724208A4 (fr) | 2021-09-01 |
US20190307785A1 (en) | 2019-10-10 |
US11058706B2 (en) | 2021-07-13 |
IL275205A (en) | 2020-07-30 |
US20220023331A1 (en) | 2022-01-27 |
AU2024200298A1 (en) | 2024-02-01 |
US20230070937A1 (en) | 2023-03-09 |
JP2021508490A (ja) | 2021-03-11 |
CN111819185A (zh) | 2020-10-23 |
CA3084824A1 (fr) | 2019-06-20 |
BR112020011670A2 (pt) | 2020-11-17 |
WO2019118919A1 (fr) | 2019-06-20 |
US20210275565A1 (en) | 2021-09-09 |
US20230201241A1 (en) | 2023-06-29 |
KR20200127152A (ko) | 2020-11-10 |
US20210161938A1 (en) | 2021-06-03 |
US11160822B2 (en) | 2021-11-02 |
US11458156B2 (en) | 2022-10-04 |
MX2020006150A (es) | 2020-11-11 |
AU2018385757A1 (en) | 2020-06-25 |
AU2018385757B2 (en) | 2023-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51155A (fr) | Compositions comprenant des polyribonucléotides circulaires et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
MA43815A (fr) | Stéroïdes neuroactifs, compositions, et leurs utilisations | |
MA50502A (fr) | Adénovirus et utilisations associées | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
MA45943A (fr) | Compositions ignifuges et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA53243A (fr) | Compositions comprenant une combinaison de ipilimumab et nivolumab | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
MA50397A (fr) | Anticorps anti-tau et leurs utilisations | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
MA53400A (fr) | Hétéromultimères alk7: actriib et leurs utilisations | |
MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA45328A (fr) | Compositions acide nucléique-polypeptide et utilisations de celles-ci | |
MA48861A (fr) | Améliorations pharmacocinétiques de chélates bifonctionnels et leurs utilisations | |
MA43567A (fr) | Anticorps pacap et leurs utilisations | |
MA44262A (fr) | Bioconjugués et utilisations de ceux-ci |